Search Results

You are looking at 31 - 40 of 1,088 items for :

  • "Lung cancer" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

Gregory P. Kalemkerian, Billy W. Loo Jr, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M. Chris Dobelbower, Afshin Dowlati, Robert J. Downey, Charles Florsheim, Apar Kishor P. Ganti, John C. Grecula, Matthew A. Gubens, Christine L. Hann, James A. Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar A. Moran, Daniel Morgensztern, Saraswati Pokharel, David C. Portnoy, Deborah Rhodes, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Charles C. Williams Jr, Karin G. Hoffmann, and Miranda Hughes

: October 10, 2018; Expiration date: October 10, 2019 Learning Objectives: Upon completion of this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Small Cell Lung Cancer Describe the

Full access

Lung Cancer Screening With Low-Dose Computed Tomography: Costs, National Expenditures, and Cost-Effectiveness

Bernardo H. L. Goulart, Mark E. Bensink, David G. Mummy, and Scott D. Ramsey

Lung cancer is the leading cause of cancer deaths in the United States, accounting for 221,000 new cancer cases and 157,000 deaths in 2011. 1 This high mortality rate occurs partly because most patients present with advanced stages, when the

Full access

Sequencing Therapy for Patients With Lung Cancer

Presented by: Gregory J. Riely

Outcomes in non–small cell lung cancer (NSCLC) are improving in part to the integration of molecular analysis and PD-L1 testing into standard practice. Classifying and treating these malignancies according to their oncogenic driver mutations and

Full access

Lung Cancer in Nonelderly Patients: Facility and Patient Characteristics Associated With Not Receiving Treatment

Elizabeth A. Nardi, Can-Lan Sun, Francisco Robert, and Julie A. Wolfson

Background Race/Ethnicity has been implied to play a role in both outcomes 1 , 2 and treatment decisions 2 – 7 in lung cancer. Despite superior survival in patients who receive therapy and a breadth of diagnostic and treatment options, a large

Full access

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

10, 2018; Expiration date: July 10, 2019 Learning Objectives: Upon completion of this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Non–Small Cell Lung Cancer Describe the rationale

Full access

The Immunobiology of Photodynamic Therapy: The Potential for Therapeutic Intervention in Lung Cancer

Susan Moffatt-Bruce

immunology, Dr. Moffatt-Bruce has turned to her current research on the use of PDT for relieving the symptoms of endobronchial disease in patients with lung cancer. Dr. Moffatt-Bruce shared the very early findings of her current study to determine whether the

Full access

Lung Cancer Survivorship: Physical, Social, Emotional, and Medical Needs of NSCLC Survivors

Melinda L. Hsu, Matthew Z. Guo, Sarah Olson, Cyd Eaton, Mary Boulanger, Michelle Turner, Mattea E. Miller, Anna Nguyen, Karol Szczepanek, Rahul Shenolikar, and Josephine L. Feliciano

, psychosocial, financial, and spiritual). 1 , 2 Understanding these needs can influence more tailored survivorship programming. 3 – 7 Lung cancer (LC) screening and improved systemic therapies across all stages of disease have improved survival for patients

Full access

Non–Small Cell Lung Cancer, Version 6.2015

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven E. Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

be able to: Integrate into professional practice the updates to the NCCN Guidelines for Non–Small Cell Lung Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Non–Small Cell Lung Cancer

Full access

Targeted Therapy for Metastatic Non–Small Cell Lung Cancer

Presented by: Gregory J. Riely

The identification of numerous oncogenic molecular alterations and the development of strategies to target these drivers have made non–small cell lung cancer (NSCLC) a complicated malignancy to manage. “NSCLC is not one disease—it’s a clinical

Full access

Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer

Philip E. Lammers and Leora Horn

Lung cancer is the leading cause of cancer-related mortality in the United States, with an estimated 228,190 new cases and 159,480 deaths in 2013. 1 More than two-thirds of patients with lung cancer will present with advanced disease. 2 The 5